Fig. 1.

(a) Dosage of anti-SARS-CoV-2 whole spike protein, RBD, S2, NP, and ME IgG and (b) IgM measured in relative antibody units (RAU) in the plasma of 10 patients with JDM onset or relapse diagnosed since the beginning of the pandemic in France. (c) Quantification of IFNα2 protein in the plasma of 33 active JDM patients followed in our clinical center (median: black dotted line), of P1 2 weeks post-onset and of P2 two weeks post-relapse. (d) Dosage of anti-SARS-CoV-2 whole spike protein, RBD, S2, NP, and ME IgG and IgM at week 2 and week 6 post-JDM relapse in P2 measured in relative antibody units (RAU)